Vir Biotechnology 거래 VIR

VirBiotechnology 실시간 차트

상품 기초

Weekly Search
Weekly
Daily
날짜 종료 변경 변동(%) 열기 높음 낮음

VirBiotechnology news

최신 뉴스

더 보기
N/A
Frances Wang 2025 5월 12, 16:00

ADA crypto price forecast: What factors influence the price of Cardano?

Cryptocurrencies
Tommy Yap 2025 5월 12, 16:00

Morning Note: Tariff Rollback Sparks Stock Rally; US CPI Watch; Bailey's Speech

Morning Note Equities
Tommy Yap 2025 5월 12, 04:00

Morning Note: US Surplus Expected; Denmark Inflation; UK Retail Sales Forecast

Morning Note EUR
Frances Wang 2025 5월 11, 16:00

How the US-China Trade War Influenced Global Commodity Markets?

Commodities
Tommy Yap 2025 5월 09, 21:00

Week Ahead: U.S. Inflation Data in Spotlight

Forex Indices
Frances Wang 2025 5월 08, 16:00

What Is Happening to the Bond Market: Bond Market Outlook 2025

Bonds
Frances Wang 2025 5월 08, 16:00

Bond Market News Today: Alphabet (GOOGL) Back to Corporate Bond Market

Bonds
Frances Wang 2025 5월 08, 16:00

Tariffs News Update: How Trump’s Policies Affect Bond Market?

Bonds

정보

스프레드

0.05

스프레드(%)

0.9470 %

레버리지

1:10

익일 이자 매수

-0.0597 %

익일 이자 매도

-0.0292 %

통화

USD

거래 시간

시장 폐장

화요일

13:31 - 19:59

월요일

13:31-19:59

수요일

13:31-19:59

목요일

13:31-19:59

금요일

13:31-19:59

분석 및 통계

열기

---

이전 종가

---

52주 최고/최저

--- – ---

시가총액

702055424

발행 주식 수

138064000

수익 날짜 (다음)

0000-00-00

배당수익률

배당락일

예상 연간 배당금

0

예상 연간 배당수익률

0

EPS

-3.83

이 상품에 대해 자세히 알아보기

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

latest_education_articles

더 보기
Trustpilot